Bioavailability Study of 2 Oral Formulations of ALXN1840
Study Identifier:
ALXN1840-HV-109
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
Date
Jan 2021 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
Date
Jan 2021 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information
Protocol Summary
The study will assess the relative bioavailability of 2 different formulations of ALXN1840 in healthy participants.
Trial Locations
Location
Status
Location
Nucleus Network Pty Ltd.
Melbourne, Victoria, Australia, 3004
Status
N/A